FINAL RESULTS OF PHASE (PH) 1/2 STUDY OF CARFILZOMIB, POMALIDOMIDE, AND DEXAMETHASONE (KPD) IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): A MULTI-CENTER MMRC STUDY

VADASTUXIMAB TALIRINE PLUS HYPOMETHYLATING AGENTS (HMA): A WELL-TOLERATED REGIMEN WITH HIGH REMISSION RATE IN FRONTLINE OLDER PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML)

PRELIMINARY RESULTS OF S55746/BCL201 (A NEW BCL2 INHIBITOR) IN RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS AND EFFECT OF CALIBRATED MODERATE MEAL ON THE PHARMACOKINETICS

ONGOING PHASE 1/2 STUDY OF INCB050465, A SELECTIVE PI3K-DELTA INHIBITOR, FOR THE TREATMENT OF PATIENTS WITH RELAPSED/REFRACTORY B-CELL MALIGNANCIES (CITADEL-101)

MECHANISTICALLY INFORMED COMBINATIONS OF SY-1425, A POTENT AND SELECTIVE RARΑ AGONIST, WITH HYPOMETHYLATING OR ANTI-CD38 TARGETED AGENTS IN AML AND MDS

CLINICAL IMPACT OF TP53 AND KMT2D MUTATIONS IN MCL RECEIVING HIGH-DOSE THERAPY AND AUTOLOGOUS TRANSPLANTATION: UPDATED RESULTS FROM THE FONDAZIONE ITALIANA LINFOMI (FIL) MCL0208 PHASE III TRIAL

SY-1425, A POTENT AND SELECTIVE RARΑ AGONIST, REPROGRAMS AML CELLS FOR DIFFERENTIATION ALONG DISTINCT LINEAGES, UNCOVERING PD MARKERS FOR CLINICAL STUDIES

PRELIMINARY RESULTS FROM A PHASE 1 STUDY EXAMINING THE NOVEL BCL-2 INHIBITOR S55746/BCL201 AS SINGLE AGENT IN PATIENTS WITH ACUTE MYELOID LEUKEMIA OR HIGH RISK MYELODYSPLASTIC SYNDROME

SAFETY AND EFFICACY OF RUXOLITINIB (RUX) IN PATIENTS WITH MYELOFIBROSIS (MF) WHO STARTED TREATMENT AT 10 MG BID AND HAD THE DOSE UPTITRATED IN THE PHASE 3B EXPANDED-ACCESS JUMP STUDY

THE USE OF CARFILZOMIB AND BORTEZOMIB IN ROUTINE CLINICAL PRACTICE: RESULTS FROM PREAMBLE, AN ONGOING, OBSERVATIONAL COHORT STUDY IN MULTIPLE MYELOMA

PRELIMINARY RESULTS FROM AN OPEN-LABEL, PHASE II STUDY OF TIPIFARNIB IN RELAPSED OR REFRACTORY PERIPHERAL T-CELL LYMPHOMA.

THE NOVEL SWITCH CONTROL INHIBITOR DCC-2618 COUNTERACTS GROWTH AND SURVIVAL OF VARIOUS NEOPLASTIC CELLS, INCLUDING MAST CELLS, EOSINOPHILS, AND MONOCYTES, IN PATIENTS WITH SYSTEMIC MASTOCYTOSIS

AN OBSERVATIONAL STUDY EVALUATING THE USE OF BENDAMUSTINE AS FIRST-LINE TREATMENT FOR CHRONIC LYMPHOCYTIC LEUKEMIA IN RUSSIA

RESULTS OF A PHASE II MULTICENTER STUDY OF OBINUTUZUMAB PLUS BENDAMUSTINE IN PTS WITH PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)

DRUG-DRUG INTERACTION POTENTIAL OF GILTERITINIB IN HEALTHY SUBJECTS AND PATIENTS WITH RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA